Compliance with ethical standards
The current study was approved by both the Institutional Medical Ethics Committee of Haseki Training and Research Hospital (May 23, 2024; approval no. 24-2024) and the Institutional Education Planning Board (approval no. 137). Prior to performing biopsies, all patients provided verbal and written consent (signed documents are available in the patient files of the hospital).
Study design
This comparative analytical cross-sectional study, a form of observational study, included a retrospective analysis of data collected prospectively in a tertiary center. The study's data was obtained from our clinic's "fusion biopsy data recording system." However, the data prior to 2019 was not included in the study, as the radiology department switched to Prostate Imaging Reporting and Data System (PIRADS) version 2.1 in 2019 [5]. Patients underwent Mp-MRI due to elevated prostate-specific antigen (PSA) (>2.5 ng/mL) and/or suspicious digital rectal examination (DRE), and among these, patients who underwent mp-MRI/TRUS fusion prostate biopsy due to the PIRADS 3/4/5 lesions that were accepted as significant lesions between January 2020 and April 2024 were included in the study (n = 616). The patients undergoing active surveillance for prostate cancer (n = 32), as well as those with a prior history of hand surgery or trauma (n = 6), missed data (n = 50) and were excluded from the study. The remaining patients were divided into two groups according to the biopsy results: Study group (n = 168): prostate cancer; Study subgroup: csPCa (n = 95); and Control group (n = 360): non-cancer (atypical small acinar proliferation, high grade prostatic intraepithelial neoplasia, prostatitis, benign prostate hyperplasia) (Figure 1). The groups were compared in terms of demographic data (age, family history, body mass index; BMI, comorbidities), patient characteristics (total PSA, PSA density, previous biopsy history, DRE), MRI characteristics (prostate volume, PIRADS score, lesion size, lesion number), patological features (number of cores, gleason score, ISUP grade), cancer stages, and right hand 2D:4D ratio. The primary endpoint was to determine the correlation with prostate cancer, while the secondary endpoint was to assess the relationship with csPCa.
Digit ratio
The measurements were conducted using a digital vernier caliper. The lengths of 2D and 4D were measured from the distal finger tip to the midpoint of each proximal crease (Figure 2). The 2D:4D ratio was determined by dividing the length of the 2D by the length of the 4D.
Prostate multiparametric magnetic resonance imaging
All mp-MRIs were conducted using either 1.5 Tesla or 3 Tesla MRI machines. The evaluated MRI sequences included T1-weighted, T2-weighted, diffusion-weighted, and dynamic gadolinium-contrast images. An experienced radiologist (XXXX) specializing in prostate MRI examined each mp-MRI image according to the parameters outlined in PI-RADS v2.1 guidelines [5]. The radiologist also determined the prostate volumes by utilizing axial and sagittal T2-weighted scans, employing the formula: height x breadth x depth/2. The radiologist was blinded to the finger measurements of the patients.
Biopsy procedure
Patients with PI-RADS 3 or more lesions underwent Mp-MRI / TRUS fusion prostate biopsy (target + systemic sampling) via transrectal technique. All patients were given antibiotic prophylaxis (fosfomycin, at a dosage of 3 g; 12 hours before and 24 hours after the biopsy, orally) and a cleansing fleet enema. The biopsies were performed using the Biojet rigid image-fusion platform (D&K Technologies GmbH, Barum, Germany) while the patient was in the lithotomy position. Local anesthesia, specifically a pudendal nerve block and periprostatic nerve block, was administered during the procedure. A disposable automatic tru-cut prostate biopsy gun with an 18G needle and biplane probe (BK-Medical, Herlev, Denmark) was utilized for sampling. A minimum of three core samples, with at least two of them being obtained from the lesion center, were taken from each suspicious lesion (Figure 3). The systematic biopsy plan involved obtaining 10–12 systematic samples from the peripheric zone of the prostate. These samples were taken from the lateral and far-lateral sections of the apical, mid, and base regions of the prostate on both sides.
Pathologic Evaluation
The formalin-fixed, paraffinized tissues were examined for pathological analysis. The tissues were appraised as 4µm thick sections and stained with Hematoxylin&Eosin (Figure 4a). The cases were evaluated by evaluating the primary and secondary Gleason patterns and categorized according to the ISUP 2014 classification (Figure 4b and 4c) [6]. Immunohistochemical analysis was employed to discriminate well-differentiated tumors from non-neoplastic glands by observing the absence of basal layer markers such as HMWCK, p63, and SMA. Immunohistochemical markers, including Nkx3, PSA, and PSAP, were employed in the assessment of poorly differentiated tumors. These markers were utilized to determine the level of differentiation and to distinguish them from other prostate tumors that share similar characteristics, such as neuroendocrine carcinoma, lymphoma, and urothelial carcinoma.
Statistical analysis
Statistical analysis of the study was performed using IBM SPSS Statistics® version 29.0.2 software (IBM Corp., Armonk, NY, USA). Numerical variables that conform to a normal distribution were displayed using the mean ± standard deviation (sd), whereas numerical variables with a distribution that deviates from normality were displayed using the median and minimum (min.)-maximum (max.) values. Categorical variables were presented as a proportion represented by a percentage symbol (%). The normality of the quantitative variables was assessed using histogram graphics, coefficient of variation, skewness and kurtosis values, normal Q-Q plot and detrended normal Q-Q plot graphics, and the Kolmogorov-Smirnov test. Given that there were 168 and 360 patients in the respective groups, the Kolmogorov-Smirnov test was used to assess the normal distribution rather than other normality tests. In this test, data with a p-value greater than .05 were considered to demonstrate conformity with the normal distribution. The Independent-Samples T test was used to compare numerical variables (age and BMI) that exhibited a normal distribution between two independent groups. On the other hand, the Mann-Whitney U test was used to compare variables that did not exhibit a normal distribution (total PSA, PSA density, prostate volume, number of significant lesions on the mp-MRI, total number of cores in biopsy, and right hand 2D:4D ratios). The Chi-square test was used to compare categorical variables (comorbidity, DRE findings) between groups. The data were examined using a 95% confidence level, and any p-values equal to or less than .05 were accepted statistically significant.